Biomarin Pharmaceutical Inc. [NASDAQ: BMRN] plunged by -$0.55 during the normal trading session on while it closed the day at $75.90.
Biomarin Pharmaceutical Inc. stock has also loss -1.39% of its value over the past 7 days. However, BMRN stock has declined by -16.81% in the 3 months of the year. Over the past six months meanwhile, it has lost -13.81% and lost -21.28% year-on date.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for BMRN stock reached $14.41 billion, with 188.60 million shares outstanding and 186.35 million shares in the current float. Compared to the average trading volume of 1.65M shares, BMRN reached a trading volume of 2859279 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Biomarin Pharmaceutical Inc. [BMRN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMRN shares is $108.06 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMRN stock is a recommendation set at 1.74. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Robert W. Baird have made an estimate for Biomarin Pharmaceutical Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 17, 2024. While these analysts kept the previous recommendation, Evercore ISI raised their target price to Outperform. The new note on the price target was released on May 14, 2024, representing the official price target for Biomarin Pharmaceutical Inc. stock. Previously, the target price had yet another raise to $100, while Wells Fargo analysts kept a Overweight rating on BMRN stock.
The Average True Range (ATR) for Biomarin Pharmaceutical Inc. is set at 1.94, with the Price to Sales ratio for BMRN stock in the period of the last 12 months amounting to 5.82. The Price to Book ratio for the last quarter was 2.84, with the Price to Cash per share for the same quarter was set at 5.51. Price to Free Cash Flow for BMRN in the course of the last twelve months was 79.26 with Quick ratio for the last quarter at 1.70.
BMRN stock trade performance evaluation
Biomarin Pharmaceutical Inc. [BMRN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.39. With this latest performance, BMRN shares dropped by -16.78% in over the last four-week period, additionally sinking by -13.81% over the last 6 months – not to mention a drop of -17.49% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMRN stock in for the last two-week period is set at 29.30, with the RSI for the last a single of trading hit 24.88, and the three-weeks RSI is set at 32.67 for Biomarin Pharmaceutical Inc. [BMRN]. The present Moving Average for the last 50 days of trading for this stock 84.74, while it was recorded at 76.86 for the last single week of trading, and 88.36 for the last 200 days.
Biomarin Pharmaceutical Inc. [BMRN]: An insightful look at the core fundamentals
Biomarin Pharmaceutical Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.70 and a Current Ratio set at 2.74.
Earnings per share (EPS) analysis for Biomarin Pharmaceutical Inc. [BMRN] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMRN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Biomarin Pharmaceutical Inc. go to 43.00%.
Biomarin Pharmaceutical Inc. [BMRN]: Institutional Ownership
The top three institutional holders of BMRN stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in BMRN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in BMRN stock with ownership which is approximately 5.8386%.
